文献速递药物不良反应与药物警戒特殊人群用药

2000-2016年儿童抗生素试验安全性报告的系统评价与Meta分析

Evaluating Safety Reporting in Paediatric Antibiotic Trials, 2000-2016: A Systematic Review and Meta-Analysis.
PubMed 文献 · Drugs · 2018-01-01

结果显示CONSORT危害报告条目完全报告率69.7%,任何不良事件中位比例22.5%,严重药物相关不良事件和因药物停药中位比例分别为0.3%和0.9%,未发现非预期年龄特异性副作用。

要点

  • 儿童抗生素试验安全性报告总体可预测且具类别特异性,未发现非预期年龄特异性副作用。
  • 严重药物相关不良事件和因药物停药罕见,中位比例分别为0.3%和0.9%。
  • 小型开放标签剂量探索高质量单臂药代动力学试验可能足以支持某些常见抗生素类别。

核心结论

  • 儿童抗生素临床试验中不良事件可预测且具类别特异性,未发现非预期年龄特异性副作用。

主要发现

  • CONSORT危害报告条目完全报告率为69.7%。
  • 任何不良事件的中位比例为22.5%,但任一身体系统均未超过8%。
  • 严重药物相关不良事件中位比例为0.3%,因药物相关停药中位比例为0.9%。
  • 局限性包括无法按年龄组分 stratify,尤其是新生儿。

关键数值与推荐

  • CONSORT 2004危害报告扩展用于评估试验报告质量。
  • 不良事件按药物类别计算中位比例及四分位距(IQR)。

临床怎么用

  • 对于某些常见抗生素类别,小型开放标签剂量探索高质量单臂药代动力学试验可能足以支持儿童用药,可借鉴成人试验已确立的安全性数据。
  • 需结合增强的药物警戒方法在常规临床实践中监测新出现的不良事件。

局限性

  • 无法按年龄组分 stratify,尤其是新生儿。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are very few options to treat multidrug-resistant bacterial infections in children. A major barrier is the duration and complexity of regulatory trials of new antibiotics. Extrapolation of safety data from adult trials could facilitate drug development for children. OBJECTIVE: We performed a systematic review on the safety of antibiotic clinical trials (CTs) in children (0-18 years) to evaluate the overall quality of safety trials conducted in children and to determine if age-specific adverse events (AEs) could be identified for specific antibiotic classes. DATA SOURCES: We searched the MEDLINE, Cochrane CENTRAL, and ClinicalTrials.gov electronic databases for trials conducted between 2000 and 2016. STUDY SELECTION: All trials in which safety was declared a primary or secondary endpoint were included. Exclusion criteria were (1) topical or inhalational route of administration; (2) non-infectious conditions; (3) administration for prophylaxis rather than treatment; (4) selected population (i.e. cystic fibrosis, malignancies, HIV and tuberculosis); and (5) design other than randomized controlled trials. Trials reporting data on both adults and children were included only if paediatric results were reported separately. DATA EXTRACTION AND SYNTHESIS: Two authors independently extracted the data. To assess the quality of published trials, the Extension for harms for Consolidated Standards of Reporting Trials (CONSORT) Statement 2004 was used. MAIN OUTCOME AND MEASURE: In order to quantitatively assess the rate of developing AEs by drug class, the numbers of overall and body-system-specific AEs were collected for each study arm, and then calculated per single drug class as median and interquartile range (IQR) of the proportions across CTs. The AEs most frequently reported were compared in the meta-analysis by selecting the CTs on the most represented drug classes. RESULTS: Eighty-three CTs were included, accounting for 27,693 children. Overall, 69.7% of CONSORT items were fully reported. The median proportion of children with any AE was 22.5%, but did not exceed 8% in any single body system. Serious drug-related AEs and drug-related discontinuations were very rare (median 0.3 and 0.9%, respectively). Limitations included the inability to stratify by age group, particularly neonates. CONCLUSIONS AND RELEVANCE: Overall, AEs in paediatric antibiotic CTs were predictable and class-specific, and no unexpected (age-specific) side effects were identified. Smaller, open-label, dose-finding, high-quality, single-arm pharmacokinetic trials seem potentially sufficient for certain common antibiotic classes, extrapolating well-established safety profiles determined from large adult efficacy trials. This approach could reduce duration and enhance subsequent registration of urgently needed new antibiotics. This will need to be combined with enhanced methods of pharmacovigilance for monitoring of emerging AEs in routine clinical practice.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Pansa P, Hsia Y, Bielicki J, et al. Evaluating Safety Reporting in Paediatric Antibiotic Trials, 2000-2016: A Systematic Review and Meta-Analysis. Drugs. 2018. PMID: 29218501. doi:10.1007/s40265-017-0850-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。